Byrne Asset Management LLC Autolus Therapeutics PLC Transaction History
Byrne Asset Management LLC
- $115 Million
- Q4 2024
A detailed history of Byrne Asset Management LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Byrne Asset Management LLC holds 250 shares of AUTL stock, worth $500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 1,500
83.33%
Holding current value
$500
Previous $5,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding AUTL
# of Institutions
109Shares Held
164MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA24.2MShares$48.4 Million0.02% of portfolio
-
Blackstone Inc New York, NY20.5MShares$41 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$33.3 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$30.5 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$24.7 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $182M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...